Effects of Intravenous (IV) Omadacycline on Gut Microbiome
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Given the clinical need to improve upon current antibiotic regimens for the treatment of C.
difficile infection with a particular focus on the impact of therapies on gut microbiome,
this study proposes to characterize the impact of Intravenous (IV) omadacycline on gut
microbiome of healthy volunteers.
Phase:
Phase 4
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborators:
High Point University Paratek Pharmaceuticals Inc University of Houston